Peptide Evidence Maturity Index

Every peptide graded on a 5-tier evidence scale using data from PubMed, ClinicalTrials.gov, OpenAlex, and FDA regulatory databases. Updated March 2026.

Evidence Tier Methodology

Tier 1 FDA Approved — FDA approved, extensive Phase III data, multiple RCTs

Tier 2 Phase II+ — Phase II+ human trials, controlled data available

Tier 3 Limited Data — Phase I or limited human data, predominantly case series

Tier 4 Preclinical — Primarily animal/in-vitro, minimal human data

Tier 5 Preclinical Only — Theoretical or strictly preclinical only

Peptide	Tier	Human Studies	RCTs	Total Trials	Active Trials	Citation Trend	FDA Status
Semaglutide	Tier 1	2,591	261	680	151	Accelerating	Approved (Ozempic/Wegovy). Compounding restricted/contested.
Tirzepatide	Tier 1	973	108	230	69	Accelerating	Approved (Mounjaro/Zepbound). Compounding restricted/contested.
Thymosin Alpha-1	Tier 1	545	62	63	11	Stable	Approved (Zadaxin - orphan). Banned from 503A compounding.
PT-141	Tier 1	86	14	10	0	Stable	Approved (Vyleesi). Eligible for compounding.
TB-500	Tier 2	572	7	16	1	Stable	Investigational. Often under thymosin beta-4 restrictions.
Cerebrolysin	Tier 2	337	61	42	3	Stable	Investigational/No FDA Status. Approved in EU/Asia.
GHK-Cu	Tier 2	60	2	2	1	Stable	Cosmetic/No FDA Status. Generally safe for topical.
BPC-157	Tier 2	47	0	2	1	Stable	Not FDA Approved. Banned from 503A/503B (Sept 2023).
Selank	Tier 2	44	3	10	0	Growing	No FDA Status. Approved in Russia.
Ipamorelin	Tier 2	23	2	2	0	Stable	Investigational. Compounded but under scrutiny.
CJC-1295	Tier 2	16	1	1	0	Stable	Investigational. No FDA Status.
Semax	Tier 3	50	1	0	0	Stable	No FDA Status. Approved in Russia.
Epitalon	Tier 3	35	0	0	0	Stable	No FDA Status. Preclinical/Russian origin.
AOD-9604	Tier 3	13	0	0	0	Stable	No FDA Status. Some GRAS status.
5-Amino-1MQ	Tier 5	0	0	0	0	Stable	No FDA Status. Preclinical only.

Click any column header to sort. Default: most credible first.

Data Sources

Data sourced programmatically from PubMed (human study counts), ClinicalTrials.gov (trial registry), OpenAlex (citation velocity analysis), and FDA regulatory databases. Analysis conducted using K-Dense Web scientific research platform with programmatic queries against PubMed, ClinicalTrials.gov, OpenAlex, and FDA databases. Last updated: March 2026.

About These Grades

Evidence tiers are assigned based on the highest level of clinical evidence available, not on therapeutic promise or popular demand. A peptide at Tier 3 may have significant preclinical potential but lacks the human trial data to support a higher classification.

For full methodology, see our evidence grading methodology.